Press Releases

LATUDA® (lurasidone), a new once-daily treatment for schizophrenia, is now available in Switzerland for the treatment of schizophrenia.Research has shown that the atypical antipsychotic, lurasidone, has a specific receptor binding profile. Symptom control and reducing...

Veristat LLC. a leading Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem Inc. . The enhanced design aims to optimize the current trial of defactinib a novel...

Oncodesign, a contract research laboratory dedicated to the discovery of new anticancer therapies, and Banook Central Imaging, a company specializing in the centralized reading of medical images, today announce the start of a partnership to expand the use of...

Almac Discovery has announced a £13million partnership with the Centre for Cancer Research and Cell Biology (CCRCB) at Queen’s University Belfast (QUB) to accelerate cancer-focused drug discovery in Northern Ireland. As part of the partnership,...

PharmaEngine Inc.  announced today that together with PharmaEngine’s partner Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) we reach the goal of patient enrollment in the global phase 3 metastatic pancreatic cancer study of PEP02 (MM-398). The total target number of patient...

Infraredx Inc. a medical device company committed to advancing the diagnosis and management of coronary artery disease today announced that it has received a $25 million equity investment from Nipro Corporation. This investment builds on...

Research by Cutting Edge Information finds that intellectual property protections in the United States encourage more pharmaceutical drug launches relative to other countries with weaker protections. According to Cutting Edge Information’s study “Pharmaceutical Launch Sequencing:...